#Biotherapeutics Cell Line Development

[bisresearch0]

Evolving Landscape of the Eosinophilic Esophagitis Market

Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease that affects the esophagus, the tube that connects the mouth to the stomach. It is characterized by the accumulation of eosinophils, a type of white blood cell, in the esophagus. These cells are typically involved in allergic reactions and inflammation, and their presence in the esophagus leads to inflammation and damage to the esophageal lining. 

Eosinophilic Esophagitis Market is expected to be driven by the rising incidence and prevalence of eosinophilic esophagitis and advancements in diagnosis and early detection.

Market Segmentation

By Drug Class

Corticosteroids

Proton Pump Inhibitors

Others

By Drug Delivery Form

Inhalation

Oral

Others

By Region

North America

Europe

Asia-Pacific

Latin America

     North America as the market leader.

Market Drivers

Growing Prevalence of EoE: As a result of improved diagnostic skills and more awareness, there are more cases being reported worldwide, which is increasing the number of patients and the need for efficient therapies.

Improved Diagnostic Methods: Advances in diagnostic technology are making it possible to discover problems earlier and more accurately, which promotes prompt action and improved patient outcomes.

Emergence of Targeted treatments: The market is expanding and unmet needs are being addressed by a plethora of novel therapeutic choices, including biologics and specialized oral treatments.

Recent Developments

November 2024: The European Medicines Agency (EMA) approved Dupixent as the first treatment for young children with eosinophilic esophagitis in the European Union, marking a significant advancement for pediatric patients.

February 2024:The U.S. Food and Drug Administration (FDA) granted approval to EOHILIA, the first and only FDA-approved oral therapy for patients aged 11 years and older with eosinophilic esophagitis.

February 2024: The FDA expanded the indication for Dupixent, developed by Regeneron and Sanofi, to include children with eosinophilic esophagitis, broadening access to this targeted biologic therapy.

Market Challenges

Inadequate Knowledge of Disease Mechanisms: In spite of increased research, the creation of more accurate and effective treatments is still hampered by our incomplete understanding of the biochemical pathways underlying the disease.

Small Diagnosed Population: Due to its relative rarity, EoE has a small patient base, which could limit the commercial feasibility of new medications, particularly in areas with low diagnostic tool accessibility or knowledge.

Leading Companies in the EoE Treatment Market

Sanofi

Takeda Pharmaceuticals

AstraZeneca

Ellodi Pharmaceuticals

Revolo Biotherapeutics

EsoCap AG

Amgen

Want to learn more about Eosinophilic Esophagitis Industry. Click Here! 

Dive deep into the knowledge pool of Healthcare Vertical. Click Here!

Future Outlook

The EoE market is on track for considerable growth, supported by heightened disease awareness, advancements in diagnostic technology, and an expanding portfolio of targeted treatment options. The market's growth is shown by recent regulatory approvals, which also show greater investment in this undertreated condition. Even while there are still issues including a small patient base and knowledge gaps about the condition, they should eventually be filled with continued R&D and industry cooperation. The market has the potential to change the way eosinophilic esophagitis is treated globally and enhance patients' quality of life if it continues to innovate.

[credenceresearchdotblog]

The Difficult to Express Proteins Market is projected to grow from USD 4,591.9 million in 2024 to USD 9,149.64 million by 2032, reflecting a compound annual growth rate (CAGR) of 9% during the forecast period. The biotechnology and pharmaceutical industries are experiencing unprecedented growth, driven by advancements in drug discovery, therapeutic development, and innovative technologies. Among the many opportunities and challenges within these industries lies a specialized yet crucial segment: the difficult-to-express proteins market. This niche, though complex, has captured the attention of researchers, developers, and investors due to its immense potential in addressing unmet medical needs.Difficult-to-express (DTE) proteins are those that are challenging to produce in sufficient quantity, purity, or activity due to inherent structural or functional complexities. These proteins often include membrane proteins, multi-subunit complexes, glycosylated proteins, and those prone to aggregation or degradation. Their importance in drug development is immense, as they often serve as therapeutic targets or biologics in treating chronic diseases, rare disorders, and cancers.

Browse the full report at https://www.credenceresearch.com/report/difficult-to-express-proteins-market

Market Drivers

Several factors are driving the growth of the difficult-to-express proteins market:

Advancements in Expression Systems: The development of robust expression platforms, such as mammalian cell lines (CHO cells), insect cell systems, yeast, and engineered microbial hosts, has significantly improved the production of complex proteins. Technologies like CRISPR-Cas9 for genome editing have further enhanced these systems, enabling customized solutions for DTE proteins.

Growing Biopharmaceutical Demand: The increasing prevalence of chronic diseases, such as cancer, autoimmune disorders, and diabetes, has led to a surge in demand for biologics, including monoclonal antibodies, vaccines, and fusion proteins. Many of these are categorized as DTE proteins.

Emerging Therapies: The rise of novel therapeutic modalities, such as antibody-drug conjugates (ADCs), bispecific antibodies, and gene therapies, has expanded the demand for complex protein scaffolds. These innovations rely on the successful production of DTE proteins to ensure efficacy and safety.

Investment in R&D: Pharmaceutical companies and research organizations are investing heavily in developing innovative methods to overcome expression challenges. Continuous funding in this space has spurred the growth of novel solutions and technologies.

Challenges in the Market

Despite advancements, the DTE proteins market faces several hurdles:

High Costs: The production of DTE proteins often requires extensive optimization, specialized facilities, and expensive reagents, driving up costs.

Technical Complexity: Producing high-quality proteins with consistent results remains a challenge, especially for proteins requiring precise glycosylation or folding.

Regulatory Hurdles: The stringent regulatory landscape for biologics and biotherapeutics adds complexity to the commercialization process.

Key Players and Innovations

Prominent players in the difficult-to-express proteins market include Lonza, Thermo Fisher Scientific, Bio-Techne, and Merck KGaA. These companies are leading the charge by investing in cutting-edge technologies and offering tailored solutions.

Innovative approaches such as cell-free expression systems, AI-driven optimization, and synthetic biology are revolutionizing protein expression. For instance, cell-free systems enable rapid prototyping of proteins without the need for live cells, reducing the time and cost associated with traditional methods.

Future Outlook

The difficult-to-express proteins market is poised for substantial growth in the coming years. The integration of artificial intelligence and machine learning to optimize protein expression processes is expected to streamline production further. Additionally, the emergence of personalized medicine and precision therapies will likely create new opportunities for DTE proteins as biomarkers or therapeutic agents.

Collaboration between academic institutions, biotech firms, and contract research organizations (CROs) will also play a pivotal role in accelerating advancements. Governments and private investors are increasingly supporting initiatives aimed at overcoming the challenges associated with protein expression.

Key Player Analysis:

Sino Biological

Thermo Fisher Scientific

StressMarq Biosciences

Novasep Holding SAS

Rentschler Biopharma SE

Enzo Life Sciences

Research and Development Systems

LifeSensors Inc.

Lucigen

BioLegend Inc.

Segments:

Based on Protein Type

Proteases

Kinases

Membrane Proteins

Others

Based on Expression Technology

Cell-free Protein Synthesis

Prokaryotic Expression Systems

SUMO Fusion Systems

Gene Fusion System

Others

Based on Application

Drug Discovery

Protein Purification

Biopharmaceuticals

Protein Therapeutics

Disease Diagnostics & Monitoring

Based on the Geography:

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/difficult-to-express-proteins-market

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com 

[shlokborde-blog]

Biotherapeutics Cell Line Development Market 2018 Grow with Significant CAGR by 2023 GlobalMarketers.biz presents most recent industry chain structure and complete analysis of Biotherapeutics Cell Line Development Market…

[solutionsandservices]

Biotherapeutics Cell Line Development Market Trends, Drivers, Strategies, Applications and Competitive Landscape 2024 Biotherapeutics Cell Line Development Market Report The report offers an overview of the Biotherapeutics Cell Line Development with the help of application segments and geographical regions (United States, Europe, China, Japan, Southeast Asia, India, Central & South America, ROW) that govern the market currently.

[meandepiphany]

HEK otherwise known as human embryonic kidney cells is an "immortalised" cell line derived from an aborted female fetus.  An immortalised cell line is a population of cells from a multicellular organism which would normally not rapidly increase indefinitely but, due to mutation, have evaded normal cellular senescence and instead can keep undergoing division. The cells can therefore be grown for prolonged periods in vitro. HEK 293 cells have been widely used in cell biology research for many years. They are also used by the biotechnology industry to produce therapeutic proteins and viruses for gene therapy. Several vaccines and biotherapeutic proteins have been already developed using HEK 293 cells.

Alex Van der Eb originally cultured the HEK cell line in the 1973. The number 293 comes from the amount of times it took to get the experiment right. 

To harvest a viable embryonic kidney for this purpose, sufficiently healthy children old enough to have adequately-developed kidneys must be removed from the womb, alive, typically by caesarean section, and have their kidneys cut out. This must take place without anaesthesia for the child, which would lessen the viability of the organs.

A comprehensive study of the genomes and transcriptomes of HEK 293 and five derivative cell lines compared the HEK 293 transcriptome with that of human kidney, adrenal, pituitary and central nervous tissue.[7] The HEK 293 pattern most closely resembled that of adrenal cells, which have many neuronal properties. 

Some advantages of HEK cells are the consistency of results and three cells are highly reproducible. However, they are prone to bacterial contamination, susceptible to viral contamination, and with  extended periods of culturing will result in the degradation of the cell’s health.

Besides use of HEK cells in vaccines they are also a known ingredient in food additives.  A biotechnology company name Senomyx claims to have "reverse engineered" human taste and aroma receptors. Senomyx was founded by prominent biochemist Lubert Stryer in 1999. Around year 2001, Senomyx patented several flavor enhancers by using "proprietary taste receptor-based assay systems", which have been previously expressed in human cell culture, in HEK293 cells. These cells were used to enhance the flavor.  Senomyx products fall under the broad category of "artificial flavors."

[globalinsightsservices]

Vitiligo – Drug Pipeline Landscape, 2023- Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

As per Global Insight services’ assessment, about 20+ prominent pharma and biotech giants are working on 20+ drugs in the Vitiligo – Drug Pipeline Landscape, 2023 globally. Vitiligo – Drug Pipeline Landscape, 2023″ report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.

“Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key –https://www.globalinsightservices.com/request-sample/GIS31222

Vitiligo is a chronic disorder that causes patches of skin to lose pigment or color, when melanocytes are attacked and destroyed, causing the skin to turn a milky-white color. There are two types of vitiligo such as nonsegmental or generalized vitiligo and segmental vitiligo. Nonsegmental or generalized vitiligo happens when the white patches appear symmetrically on both sides of body, such as on both hands or both knees. Segmental vitiligo happens when the white patches are only on one segment or side of body, such as a leg, one side of the face, or arm.

The cause of vitiligo is unknown but researchers believe that vitiligo as an autoimmune disease. It’s is not clear exactly what causes these pigment cells to fail or die. Researchers suggest that it may be related to a disorder of the immune system (autoimmune condition), family history (heredity), a trigger event, such as stress, severe sunburn or skin trauma, such as contact with a chemical.

Symptoms of Vitiligo include patchy loss of skin color, premature hair graying, loss of color in the tissues that line the inside of the mouth and nose.

Get Customized report as per your requirements – https://www.globalinsightservices.com/request-customization/GIS31222/

Diagnosis of vitiligo is easy as the white patches are visible on the skin, but doctors use a Wood’s lamp, which shines ultraviolet (UV) light onto the skin to help differentiate from other skin conditions. Doctors may also suggest for other tests can include blood tests to check for other autoimmune diseases, an eye exam to check for uveitis, and a skin biopsy. Doctors can examine the tissue for the missing melanocytes seen in the depigmented skin of a person with vitiligo.

Treatments of Vitiligo can include medicines or medicated skin creams, use of light (phototherapy) to help return color to the skin, depigmentation and dermatologists may consider surgical techniques for long-standing segmental vitiligo.

There are many companies that are active in the development of vitiligo drugs. Some of these companies include AbbVie, Ahammune Biosciences Pvt. Ltd, Arcutis Biotherapeutics, Arrien Pharmaceuticals, Bristol-Myers Squibb etc.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Vitiligo treatment such as Ritecitinib, Afamelanotide, VYN201, and others. Key players involved in the development of therapies to treat Vitiligo are AbbVie Inc, Pfizer, VYNE Therapeutics and others. One drug is under Phase III clinical trials and ten drugs are in Phase II clinical trials and some other drugs are under Phase I, IND/CTA filed, preclinical and discovery stages of development. In Oct 2022, Clinuvel Pharmaceuticals Ltd has enrolled first patient in a new clinical study (CUV104) evaluating the safety and efficacy of afamelanotide.

Buy your copy now: https://www.globalinsightservices.com/checkout/single_user/GIS31222

Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like –

– Late-stage products (Phase III) – Mid-stage products (Phase II) – Early-stage product (Phase I) – Pre-clinical and Discovery stage candidates – Discontinued & Inactive candidates

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

Contact Us:

Global Insight Services LLC 16192, Coastal Highway, Lewes DE 19958 E-mail: info@globalinsightservices.com Phone: +1–833–761–1700 Website: https://www.globalinsightservices.com/

[marketresearchnews1242]

What You Need To Know About The Growing Opportunities In The CMO/CDMOS Biotechnology Market

Global revenue from the CMO/CDMO biotechnology market stands at US$ 10.2 Bn in 2022, with the worldwide market estimated to surge ahead at a CAGR growth value of 11.6% to reach a valuation of around US$ 34.1 Bn by the end of 2033.

According to Persistence Market Research, the stand-alone services segment of the CMO/CDMO biotechnology market based on the services secured a market value of US$ 5.9 Bn in 2022. Demand for stand-alone services will remain the maximum through the course of the forecast period. Throughout the forecast period, the demand for stand-alone services will continue to be at its highest level.

A Contract Manufacturing Organization (CMO) or Contract Development and Manufacturing Organization (CDMO) offers a wide range of services such as fermentation, cell line optimization, cell banking and protein expression. This allows companies to outsource their work instead of maintaining an in-house team to develop drugs and devices.

The market for these organizations is highly competitive with several key players such as Wakamoto Pharmaceutical Co., Ltd., Recipharm AB, Lonza Group Ltd., Wuxi PharmaTech (Cayman), Inc., Corden Pharma GmbH, Kemwell Biopharma Pvt Ltd, Fujifilm Diosynth Biotechnologies, Enmex SA de CV, CordenPharma Plc, API Capital Sdn Bhd among others. Each organization provides a wide variety of services depending on the specific needs of customers.

Competitive Landscape

Key players are concentrating on expansion in emerging regions and new revised product manufacturing. Market participants are also working to strengthen their expansion, new product launches, and improved distribution channels such as online sources of advertisement.

For instance:

For instance, Iovance Biotherapeutics chose Avid Bioservices in August 2020 to spearhead process development through cGMP manufacture of IOV-3001, an innovative anti-cancer medication candidate and new IL-2 analogue.

Fujifilm Diosynth Biotechnologies in April 2021, announced the establishment of its new Microbial production facility in the U.K. The aim of this expansion was to triple the existing microbial production. This new production facility was equipped with 2*2000L of fermenters and modular purification suits.

With their increasing capabilities and expertise, it's easy to understand why investing into solutions offered by CMOs and CDMOs are becoming increasingly attractive!

 Buy full Report Now: https://www.persistencemarketresearch.com/checkout/32516